{"protocolSection":{"identificationModule":{"nctId":"NCT06482775","orgStudyIdInfo":{"id":"2015-002506-37"},"organization":{"fullName":"Region Skane","class":"OTHER"},"briefTitle":"Dexmedetomidine for Analgosedation to Newborn Infants During Neonatal Intensive Care","officialTitle":"Dexmedetomidine for Analgosedation to Newborn Infants During Neonatal Intensive Care - a Prospective Pharmacokinetic/ Pharmacodynamic/ Pharmacogenetic Observational Study.Cohort 3 in The SANNI Project."},"statusModule":{"statusVerifiedDate":"2021-06","overallStatus":"WITHDRAWN","whyStopped":"Problems with the study costs after Covid-19","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-06-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-12-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2021-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-08-04","studyFirstSubmitQcDate":"2024-06-27","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-27","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Region Skane","class":"OTHER"},"collaborators":[{"name":"Lund University","class":"OTHER"},{"name":"Karolinska Institutet","class":"OTHER"},{"name":"Helsinki University Central Hospital","class":"OTHER"},{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust","class":"OTHER"},{"name":"Örebro University, Sweden","class":"OTHER"},{"name":"The Swedish Research Council","class":"OTHER_GOV"},{"name":"University of Tartu","class":"OTHER"},{"name":"University of Colorado, Denver","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A prospective pharmacokinetic (PK), pharmacodynamic (PD) and pharmacogenetic (PG) observation study, including the PK/PD/PG relationship, on dexmedetomidine administered for analgesia and sedation to postsurgical and other newborn sick infants needing the drug for clinical reasons during neonatal intensive care. Phase III - therapeutic confirmatory study.","detailedDescription":"The patients will be treated according to clinical guidelines and judgement as decided by the responsible clinical doctor.\n\nThe dosing and administration of dexmedetomidine will be implemented according to an algorithm based on pain scoring results.\n\nApart from extra blood sampling and extended bedside monitoring for amplitude-integrated EEG (aEEG), Near InfraRed Spectroscopy (NIRS), and Galvanic Skin Response (GSR) the care is according to clinical routine.\n\nIn total 100 infants will be included."},"conditionsModule":{"conditions":["Intensive Care, Neonatal","Analgesia","Hypnotics and Sedatives"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"Whole blood"},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"dexmedetomidine","description":"Infusion of dexmedetomidine 4 microgram/mL.","interventionNames":["Drug: dexmedetomidine"]}],"interventions":[{"type":"DRUG","name":"dexmedetomidine","description":"The dosing and administration will be implemented according to an algorithm based on pain scoring results","armGroupLabels":["dexmedetomidine"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Pharmacokinetics (PK) of dexmedetomidine","description":"The plasma concentration will be analysed and then further reported using NONMEM® (Non-linear Mixed Effect Modelling) population-based PK modelling.","timeFrame":"Repeated blood samples (5 minutes after the loading dose until 12 hours after stop of infusion)"},{"measure":"Neurophysiologic response; global brain network function in relation to PK","description":"Assessment of global brain network function will be based on Activation Synchrony Index.","timeFrame":"Baseline until 12 hours after stop of infusion"}],"secondaryOutcomes":[{"measure":"Change in heart rate, HR, (hemodynamic response) in relation to PK (PK/PD)","description":"HR will be monitored 1/second according to clinical routine in the neonatal intensive care, and concomitantly downloaded into the aEEG (amplitude integrated electroencephalography) monitor. The change will be described as percentage increase/decrease. The change from baseline response in heart rate using longitudinal models of data on these endpoints following dexmedetomidine administration using a population PK/PD approach.","timeFrame":"Baseline until 12 hours after stop of infusion"},{"measure":"Change in mean arterial blood pressure, MABP, (hemodynamic response) in relation to PK (PK/PD)","description":"MABP will be monitored 1/second according to clinical routine in the neonatal intensive care, and concomitantly downloaded into the aEEG (amplitude integrated electroencephalography) monitor. The change will be described as percentage increase/decrease. The change from baseline response in MABP using longitudinal models of data on these endpoints following dexmedetomidine administration using a population PK/PD approach.","timeFrame":"Baseline until 12 hours after stop of infusion"},{"measure":"Change in/association between Near Infrared spectroscopy, NIRS, in relation to PK.","description":"NIRS will be monitored 1/second according to clinical routine in the neonatal intensive care, and concomitantly downloaded into the aEEG (amplitude integrated electroencephalography) monitor. The change will be described as percentage increase/decrease","timeFrame":"Once per second (from baseline until 12 hours after stop of infusion)"},{"measure":"Procedural pain response in relation to PK: assessed with change in galvanic skin response","description":"Procedural pain response at a short standardized pain stimulation;","timeFrame":"Once during treatment with dexmedetomidine"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Newborn infants: - born 34+0 gw with a need for dexmedetomidine for analgesic and/or sedative treatment after postnatal surgical correction of congenital malformations and who will be cared for in the PICU (postoperative intensive care unit) and in a some few cases in the NICU (neonatal intensive care unit), or\n* with a corresponding age of 37 gw, who are in need for dexmedetomidine according to clinical judgment and cared for in the NICU.\n* Existing arterial or venous cannulas/catheters for repeated nontraumatic blood sampling\n* Informed and written parental consent obtained before study start.\n\nExclusion Criteria:\n\n* Infant older than age corresponding to gw 46+0\n* Previous treatment with the dexmedetomidine within 72 hours (only for postoperative infants).\n* Congenital cardiac malformations requiring surgery on extracorporeal circulation and treatment with hypothermia.\n* Ongoing renal replacement treatment\n* Any serious medical condition or ethical issues that could, in the investigators opinion, interfere with the study procedures.","healthyVolunteers":false,"sex":"ALL","maximumAge":"27 Days","stdAges":["CHILD"],"studyPopulation":"Sick newborn infants in need of intensive care.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Elisabeth Norman, MD","affiliation":"Region Skane","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Skane University Hospital","city":"Lund","zip":"221 85","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"facility":"Karolinska Universitetssjukhuset","city":"Stockholm","zip":"171 76","country":"Sweden","geoPoint":{"lat":59.33258,"lon":18.0649}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"interventionBrowseModule":{"meshes":[{"id":"D000020927","term":"Dexmedetomidine"}],"ancestors":[{"id":"D000006993","term":"Hypnotics and Sedatives"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000058647","term":"Adrenergic alpha-2 Receptor Agonists"},{"id":"D000000316","term":"Adrenergic alpha-Agonists"},{"id":"D000000322","term":"Adrenergic Agonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M22662","name":"Dexmedetomidine","asFound":"Twice daily","relevance":"HIGH"},{"id":"M10043","name":"Hypnotics and Sedatives","relevance":"LOW"},{"id":"M4032","name":"Analgesics","relevance":"LOW"},{"id":"M20786","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20746","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3668","name":"Adrenergic alpha-Agonists","relevance":"LOW"},{"id":"M3673","name":"Adrenergic Agonists","relevance":"LOW"},{"id":"M20504","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}